Johnson & Johnson invests over $1 billion in cell therapy manufacturing facility
New England Council member Johnson & Johnson has announced a more than $1 billion investment to build a next-generation cell therapy manufacturing facility in Montgomery County, PA. The facility, to be operated by subsidiary Janssen Biotech, will expand the company’s capacity to produce advanced treatments for cancer, immune-mediated, and neurological diseases.
The state-of-the-art facility, located near J&J’s existing research campus north of Philadelphia, will focus on cell therapy treatments including those targeting multiple myeloma, a cancer that attacks white blood cells in the bone marrow. The project is expected to create more than 4,000 construction jobs during development and 500 biomanufacturing positions when fully operational. J&J is also planning two additional expansion projects at the Spring House R&D site, including a new cell engineering and analytical sciences facility and a CAR-T testing and manufacturing center aimed at delivering personalized therapies more quickly.
“By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families,” said Johnson & Johnson Chairman and CEO Joaquin Duato.
The New England Council commends Johnson & Johnson for its continued investment in life sciences innovation and advanced manufacturing, furthering the development of transformational medicines for patients nationwide.
Read more in the Boston Business Journal and Johnson & Johnson’s press release.